RESEARCH MONOGRAPH · KDC-MN-355

Famotidine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

85/100

H2 blocker thats quietly more interesting than the heartburn rep, especially in mast cell research

Famotidine is the H2 receptor antagonist most people interact with as an over-the-counter acid reducer, but the pharmacology has some interesting wrinkles that the gastroenterology framing misses.

Mechanistically it's clean. Competitive H2 antagonism, selective enough that anticholinergic and CNS effects are minimal (much lower than cimetidine, less CYP interaction than ranitidine), and pharmacokinetics that are predictable across most populations. The acid-suppression effect is well-characterized and reliable.

What's more interesting from a research angle is the mast cell story. H2 receptors are expressed on mast cells and modulate degranulation, and famotidine plus an H1 antagonist (the classical H1-H2 combination used in mast cell activation syndrome research and clinical management) has a coherent mechanistic basis for damping mast cell mediator release. The MCAS literature is messy but the H1-H2 combination is in most working protocols for a reason. Theoharides and Akin have written extensively on this.

Then there's the COVID-19 famotidine story. Early observational data out of New York hospitals (Freedberg, Tomera) suggested an association between famotidine use and improved outcomes, which got everyone interested for a while. The mechanism hypotheses ranged from direct viral protease interaction to histamine receptor modulation of inflammation, and the randomized trials that followed were mixed. Honestly we think the signal was probably modest and the mechanism remains unclear, but the episode is a useful case study in how observational signals can move faster than mechanism.

Sourcing is excellent. Standard small molecule, the free base is stable, salt forms widely available, USP-grade reference standards trivial to source. Research-grade famotidine is one of the cheapest H2 probes you can buy.

What we like for research is using famotidine as a clean H2 probe in mast cell, immune, and gastric physiology studies. The selectivity is good and the in vivo pharmacokinetics are well-mapped.

What we dont love is the marketing of OTC famotidine for anxiety and stress, which is based on the weakest possible interpretation of H2 effects on cortical histaminergic signaling. There's no solid clinical evidence there and the framing leans on the kind of receptor-presence-equals-functional-effect reasoning that almost never holds up.

Evidence: 88
Mechanism: 85
Reliability: 85
Safety: 92
Sourcing: 92
Value: 92
Signal: 65
Staying power: 78

Plain-language summary Intrigue 48 / 100

Famotidine, sold as Pepcid, is the most prescribed H2 antihistamine for acid-related gastrointestinal conditions. Unlike H1 blockers used for allergies, H2 blockers reduce gastric acid by blocking histamine signaling at parietal cells in the stomach lining. It is widely used for peptic ulcer disease, GERD, and acid-related upper GI symptoms, with a clean safety profile that allowed OTC availability. The compound briefly attracted attention during the COVID-19 pandemic when retrospective data suggested possible benefit, but prospective trials have been mixed and the proposed anti-inflammatory mechanism remains speculative. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

H2 receptor antagonist

A second-generation H2 antihistamine; an acid-suppressing agent for peptic ulcers and GERD; investigated for anti-inflammatory and COVID-19 effects.

Abstract

Famotidine (3-({2-[(diaminomethylene)amino]-1,3-thiazol-4-yl}methylsulfanyl)-N-sulfamoyl-propanimidamide; CAS 76824-35-6; molecular formula C8H15N7O2S3; molecular weight 337.45) is a second-generation H2 receptor antagonist developed at Yamanouchi (now Astellas) and approved by the FDA in 1986 (Pepcid). The compound competitively inhibits H2 receptors on gastric parietal cells, reducing histamine-stimulated gastric acid secretion. H2 selectivity over H1 is greater than 1000-fold. Plasma half-life is approximately 2 to 4 hours; renal excretion is the principal clearance pathway. Approved indications: peptic ulcer disease, GERD, Zollinger-Ellison syndrome. The compound attracted attention during the COVID-19 pandemic after observational data suggested possible benefit; randomized controlled trials have produced mixed results, with proposed mechanisms including TMPRSS2 inhibition, sigma-1 modulation, and anti-inflammatory H2 antagonism on immune cells. Used as the canonical H2 antagonist in research.

Mechanism of action

Selective H2 receptor antagonism (>1000-fold over H1); reduces gastric acid secretion. Possible anti-inflammatory effects on immune cells.

Reported research dose ranges

Clinical 20 to 40 mg in the published literature.

References

Howden CW, et al. Famotidine therapy for peptic ulcer disease. Drugs 1991.
Freedberg DE, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients. Gastroenterology 2020.
Smith JM, et al. Famotidine and COVID-19: randomized trial. Ann Intern Med 2022.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-355

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Famotidine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs